
---
title: '当代狂犬病疫苗及不断优化的接种方案（2）'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=801257'
author: 科学网
comments: false
date: Tue, 02 Nov 2021 08:14:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=801257'
---

<div>   
<p style="line-height: 200%"><strong><span style="font-family: Italic;line-height: 200%;font-size: 32px"><span style="font-family:Italic">当代狂犬病疫苗及不断优化的接种方案（</span>2）</span></strong></p><p style="text-indent: 64px;line-height: 200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">本文主要取材于今年</span>6月出版的专业杂志《</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF">Viruses</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">》</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">上的一篇综述论文（见参考文献），原文的两位作者来自美国堪萨斯州立大学（曼哈顿），该大学是国际著名的狂犬病研究机构之一。该文的</span>3位审稿人分别是美国CDC主管狂犬病研究的现负责人和前负责人，以及美国农业部主管狂犬病问题的负责人。</span></strong></p><p style="text-indent: 64px;line-height: 200%"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px;background: #FFFFFF"><span style="font-family:KaiTi">本文提供的权威资料可帮助公众更深入认识狂犬病和狂犬病疫苗：知道如何判断狂犬病疫苗的有效性，了解狂犬病疫苗接种方案不断优化的历程和未来发展趋势。</span></span></strong></p><p><span style="font-family: 'Palatino Linotype';font-size: 13px"> </span></p><p style="margin-left: 0;text-indent: 55px;line-height: 200%"><strong><span style="font-family: SimSun;line-height: 200%;color: #2E3033;letter-spacing: 0;font-size: 24px;background: #FFFFFF">2.<span style="font-family:SimSun">数据比较</span></span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">显然，国家卫生机构希望建立新的或更新他们目前的人类狂犬病预防建议，需要考虑和评估广泛的数据。然而，如上文所述，使用不同疫苗、</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">途径和</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种方案</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的大量已公布信息可能使直接比较数据变得困难和复杂。目前，在比较</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">IM</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（肌肉内接种</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">方案和</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">ID</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（皮内接种</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">方案的数据时，还没有精确的科学方法来证实在各个可能的免疫学方面的绝对等效性。然而，当比较来自狂犬病</span>IM和ID疫苗接种试验的同行评审的已发表临床数据时，有</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">三个标准</span></span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">可以作为验证</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">等效性</span></span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的基准。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> </span></p><p style="margin-left: 0;text-indent: 0;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px"><span style="font-family:Palatino Linotype">表</span>1</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px"> .  </span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px">免疫原性、</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px">效力</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px">和记忆反应。</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">暴露后预防</span>(PEP</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">)或</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露前</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">预防</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">(Pre</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">P</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）在采用</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">肌</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">肉</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">内</span>(IM</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">)或</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">皮内</span>(ID</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">)疫苗接</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">种</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">后，确认</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">具有</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">免疫原性证</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">据</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">所需的建议最低抽血次数</span>;</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">在经</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">证实</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病暴露后</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">确证</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">已获得针对狂犬病的保护所需的</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">证据</span>;</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> </span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">先前通过</span>IM或ID途径接受PreP的人</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，为证明</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">在</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">加强针</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">后出现</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">保护</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">反应</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">建议应当提供</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的证据。</span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">狂犬病毒中和抗体</span>(RVNA</span></span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">)水平应使用一种有效的RVNA试验进行评估。NA</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">代表</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">不适用</span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。</span></p><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 12px"> </span></p><table><tbody><tr class="firstRow"><td width="19" valign="top" rowspan="2" style="padding: 0px 7px; border-width: 1px; border-color: windowtext;"><br></td><td width="47" valign="top" rowspan="2" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top-width: 1px; border-top-color: windowtext; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: Bold;font-size: 16px">标准</span></strong></p></td><td width="429" valign="top" colspan="2" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top-width: 1px; border-top-color: windowtext; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: Bold;font-size: 16px">所需数据</span></strong></p></td><td width="209" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top-width: 1px; border-top-color: windowtext; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: Bold;font-size: 16px">补充数据</span></strong></p><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 16px"> </span></p></td></tr><tr><td width="252" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><strong><span style="font-family: Bold;font-size: 16px">启动PreP或PEP后确认RVNA应答的最</span></strong><strong><span style="font-family: Bold;font-size: 16px">少</span></strong><strong><span style="font-family: Bold;font-size: 16px">抽血次数和建议</span></strong><strong><span style="font-family: Bold;font-size: 16px">的最短抽血取样</span></strong><strong><span style="font-family: Bold;font-size: 16px">时间</span></strong><strong><span style="font-family: Bold;font-size: 16px">。</span></strong></p></td><td width="178" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><strong><span style="font-family: Bold;font-size: 16px">患者</span></strong><strong><span style="font-family: Bold;font-size: 16px">暴露于</span></strong><strong><span style="font-family: Bold;font-size: 16px">已确诊的狂犬病动物</span></strong><strong><span style="font-family: Bold;font-size: 16px">，</span></strong><strong><span style="font-family: Bold;font-size: 16px">启动PEP后确认</span></strong><strong><span style="font-family: Bold;font-size: 16px">患者</span></strong><strong><span style="font-family: Bold;font-size: 16px">存活的最</span></strong><strong><span style="font-family: Bold;font-size: 16px">短</span></strong><strong><span style="font-family: Bold;font-size: 16px">抽</span></strong><strong><span style="font-family: Bold;font-size: 16px">血取样</span></strong><strong><span style="font-family: Bold;font-size: 16px">时间</span></strong><strong><span style="font-family: Bold;font-size: 16px">。</span></strong></p></td><td width="209" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top-width: 1px; border-top-color: windowtext; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: Bold;font-size: 16px">考虑额外的抽血日期</span></strong><strong><span style="font-family: Bold;font-size: 16px">。</span></strong></p><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 16px"> </span></p></td></tr><tr><td width="19" valign="top" style="padding: 0px 7px; border-left-width: 1px; border-left-color: windowtext; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: SimSun;font-size: 16px">1</span></p></td><td width="47" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: 'Palatino Linotype';font-size: 16px">免疫原性</span></strong></p></td><td width="252" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">PrEP (ID或IM):第0天和第35天</span><span style="font-family: 'Palatino Linotype';font-size: 16px">。</span></p><p><span style="font-family: 'Palatino Linotype';font-size: 16px">PEP (ID或IM):第0、14和28天</span><span style="font-family: 'Palatino Linotype';font-size: 16px">。</span></p></td><td width="178" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 16px">NA</span></p></td><td width="209" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">补充采血日期将提供额外的数据点来监测滴度随时间的上升和下降。</span></p></td></tr><tr><td width="19" valign="top" style="padding: 0px 7px; border-left-width: 1px; border-left-color: windowtext; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: SimSun;font-size: 16px">2</span></p></td><td width="47" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: SimSun;font-size: 16px">有效性</span></strong></p></td><td width="252" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">PEP (ID或IM):第0、14和28天</span><span style="font-family: 'Palatino Linotype';font-size: 16px">。</span></p></td><td width="178" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">PEP (ID或IM):PEP首</span><span style="font-family: 'Palatino Linotype';font-size: 16px">针</span><span style="font-family: 'Palatino Linotype';font-size: 16px">注射后一年</span><span style="font-family: 'Palatino Linotype';font-size: 16px">。</span></p></td><td width="209" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">包括抽血作为临床试验的一部分，以测试有效性</span><span style="font-family: 'Palatino Linotype';font-size: 16px">，</span><span style="font-family: 'Palatino Linotype';font-size: 16px">有助于确认PEP后的免疫反应。</span></p></td></tr><tr><td width="19" valign="top" style="padding: 0px 7px; border-left-width: 1px; border-left-color: windowtext; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: SimSun;font-size: 16px">3</span></p></td><td width="47" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><strong><span style="font-family: Bold;font-size: 16px">记忆反应</span></strong></p></td><td width="252" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p><span style="font-family: 'Palatino Linotype';font-size: 16px">PreP系列(ID或IM)第一次注射后1年，记录加强</span><span style="font-family: 'Palatino Linotype';font-size: 16px">针</span><span style="font-family: 'Palatino Linotype';font-size: 16px">前的基线滴度，以及加强</span><span style="font-family: 'Palatino Linotype';font-size: 16px">针</span><span style="font-family: 'Palatino Linotype';font-size: 16px"> 后7至14天</span><span style="font-family: 'Palatino Linotype';font-size: 16px">。</span></p></td><td width="178" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 16px">NA</span></p></td><td width="209" valign="top" style="padding: 0px 7px; border-left: none; border-right-width: 1px; border-right-color: windowtext; border-top: none; border-bottom-width: 1px; border-bottom-color: windowtext;"><p style=";text-align:center"><span style="font-family: 'Palatino Linotype';font-size: 16px">NA</span></p></td></tr></tbody></table><p><span style="font-family: SimSun;font-size: 12px"> </span></p><p><strong><span style="font-family: SimSun;font-size: 21px"><span style="font-family:SimSun">表</span>1<span style="font-family:SimSun">的英文版</span></span></strong></p><p style="margin-left: 0;text-indent: 0;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=801257" title alt="image.png" width="745" height="352" style="width: 745px; height: 352px;" referrerpolicy="no-referrer"> </span></p><p style="margin-left: 0;text-indent: 49px;line-height: 200%"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 21px">2．1． 免疫原性</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PEP和PreP后产生的RVNA</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（狂犬病毒中和抗体）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">是疫苗接种后</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">成功地产生了</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">免疫反应的重要</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">证据</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">。事实上</span>,建议暴露于疑似或确诊患狂犬病动物</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的病人进行的</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PEP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种还</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">包括</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">被动免疫（</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">passive immunity </span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">程序</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">以确保</span>RVNA(</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">即</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病免疫球蛋白</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">RIG）的 接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">,</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">RIG的接种时间应在接种PEP</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">第一</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">疫苗</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">的同时或此后最多</span>7天之内</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> <span style="font-family:Palatino Linotype">。以</span>RIG形式出现的被动免疫，通过使伤口部位能够尽快获得RVNA，消除</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">在</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">创伤暴露期间可能</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">入侵</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的狂犬病毒，有助于降低疾病进展的风险。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">在接种第一</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">疫苗后，如果超过</span>7天，患者自身的免疫系统就会开始产生RVNAs(主动免疫)</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，此时就不应当再接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">RIG</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（狂犬病免疫球蛋白）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。一般来说，在接种第一</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">疫苗后，患者的免疫系统产生可检测到的</span>RVNA需要7 ~ 14天。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">基于上述原因，免疫原性是新</span>PEP方案概念验证的第一步。在第14天或之前检测到RVNA的存在被认为是正在考虑的PEP方案产生强大的免疫反应的证据。</span><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">还</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">没有一个</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">确定的</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">滴度值已经被证明对人类有</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:Palatino Linotype">绝对的</span> </span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">保护作用。</span></strong></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">显然，进行一项临床试验，让人类受到狂犬病毒的挑战，以确定确切的保护性抗体水平，将是不道德的。然而，</span><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px"><span style="font-family:Palatino Linotype">开始接种疫苗后第</span>14天的血清学滴度为0.5 IU / mL被认为是</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">有</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">足够免疫</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">力的</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #FF0000;font-size: 19px">证明</span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">。在检测</span>RVNA值时，重要的是要利用一种实际测量</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">中和抗体</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">neutralizing antibody </span></span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 13px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">而不是</span><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">结合抗体</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> binding antibody</span></span></strong><strong><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span></span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的方法。</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">快速荧光</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">灶</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">抑制试验</span>(RFFIT</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">)和</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">荧光抗体中和试验</span>(FAVN)</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">均适用于此目的。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">大多数评估新疗法或替代疗法疗效的临床试验还包括评估临床试验中不同时间点</span>RVNA水平的方案，以跟踪免疫反应的动力学。目前被列入</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">WHO</span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">资格预审</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（</span></span><span style="text-decoration:underline;"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"> prequalified</span></span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">的四种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">CCV</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">均进行了临床试验并公布了数据，证明它们在</span>IM PEP和ID PEP后确实产生了强大的免疫应答，并确认RVNA在开始接种疫苗后的第14天</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">就</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">存在。</span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">建议</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">因</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">职业或爱好使其</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">狂犬病风险增加的人进行</span><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">PreP，</span></strong><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">因此应在</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">暴露</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">发生前进行。尽管确认一种新的</span>PreP方案引起RVNA的产生很重要，但PreP的目标不是对最近的暴露做出尽快产生RVNA的反应。相反，PreP的目的是消除使用RIG</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">（狂犬病免疫球蛋白）</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">的需要，并启动免疫系统，以便在未来暴露于狂犬病的情况下，引发对加强疫苗的快速免疫反应。因此，一些检查新的</span>PreP方案的研究没有包括第14天的血液样本，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">而是</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">在临床试验的时间轴晚些时候</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">例如第</span>35天</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">提取血液样本。在检查新的</span>PreP方案时，证明疫苗或方案引起免疫反应是确认接种过疫苗的人在注射加强</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">或一系列疫苗时也有快速</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">回忆</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">反应的第一步。</span> </span></p><p style="margin-left: 0;text-indent: 43px;line-height: 200%"><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">在</span>PreP临床试验中，在开始接种疫苗后的第14至35天抽血并进行检测以确认RVNA的存在，可以提供所需的证据，以确认所考虑的方案是</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">具有</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">免疫原性的。在许多研究中，通过</span>IM和ID途径对PreP的免疫反应进行了比较</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">。</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">随着新数据的获得，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">WHO</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">更新了对</span>PreP的建议。目前，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">WHO</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">对</span>PreP的建议包括两</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">一周</span>ID </span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种方案，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">和三</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">针</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">ID或IM</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">接种</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">方案，</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px">后一方案整个</span><span style="font-family: 'Palatino Linotype';line-height: 200%;font-size: 19px"><span style="font-family:Palatino Linotype">疗程为</span>21 - 28天。</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:49px;padding:0 0 0 0 ;text-autospace:ideograph-numeric;line-height:200%;background:rgb(255,255,255)"><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #333333;letter-spacing: 0;font-size: 21px">（</span></strong><strong><span style="font-family: 'Palatino Linotype';line-height: 200%;color: #333333;letter-spacing: 0;font-size: 21px">未完待续）</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 24px">参考文献：</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">Briggs, D.J.; Moore, S.M. </span><strong><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">The Route of Administration of Rabies Vaccines: Comparing the Data. </span></strong><em><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">Viruses</span></em><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px"> 2021, 13, 1252.  </span><a href="https://www.mdpi.com/1999-4915/13/7/1252" target="_blank"><span style="font-family: 'Palatino Linotype';color: #6666CC;letter-spacing: 0;font-size: 19px">https://www.mdpi.com/1999-4915/13/7/1252</span></a><span style="font-family: 'Palatino Linotype';color: #333333;letter-spacing: 0;font-size: 19px">   </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">相关博文：</span></strong></p><p style="margin: 16px 0px; text-indent: 0px; padding: 0px; line-height: 28px; background: rgb(255, 255, 255);"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1310423" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=801258" title alt="image.png" referrerpolicy="no-referrer"> 当代狂犬病疫苗及不断优化的接种方案（</span>1）</span></span></strong></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-11-01</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1310513.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1310513.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1310423.html" target="_black">当代狂犬病疫苗及不断优化的接种方案（1）</a><br>                    <!--大赛结束-->
                                        
  
</div>
            